A Phase II Trial of Samarium 153 Followed by Salvage Prostatic Fossa 3D-CRT or IMRT Irradiation in High-Risk, Clinically Non-Metastatic Prostate Cancer After Radical Prostatectomy
Latest Information Update: 10 Nov 2021
At a glance
- Drugs Samarium 153 lexidronam (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 08 Aug 2012 Planned End Date changed from 1 Oct 2012 to 1 Nov 2015 as reported by ClinicalTrials.gov (NCT00551525).
- 08 Aug 2012 Planned End Date changed from 1 Oct 2012 to 1 Nov 2015 as reported by ClinicalTrials.gov (NCT00551525).
- 05 Nov 2008 Planned end date changed from 1 Aug 2010 to 1 Oct 2012 as reported by ClinicalTrials.gov.